SCHEMBL20913786

SCHEMBL20913786

CNC(=O)c1cc(C(=O)NC2CCOCC2)cc(Cc2cccc(OC)c2)n1

nearest known ligand 0.77

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 17/20 0.77
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
HPGDS O60760 1/20 0.50
DRD4 P21917 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19661883 0.93 BRD4 (0.75) BRD4DRD4
SCHEMBL20913763 0.87 BRD4 (1.00) BRD4
SCHEMBL20929845 0.86 BRD4 (0.77) BRD4
SCHEMBL22593043 0.86 BRD4 (0.77) BRD4
SCHEMBL19662383 0.84 BRD4 (0.76) BRD4
SCHEMBL29830427 0.84 BRD4 (0.76) BRD4
SCHEMBL19661890 0.82 BRD4 (0.76) BRD4
SCHEMBL20929910 0.82 BRD4 (0.60) BRD4
SCHEMBL19662850 0.82 BRD4 (0.70) BRD4
SCHEMBL20929888 0.82 BRD4 (0.88) BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10934272-B2 Pyridyl derivatives as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2021-03-02 US claimed
US-20190119248-A1 PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2019-04-25 US claimed
US-10934272-B2 Pyridyl derivatives as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2021-03-02 US disclosed
US-10934272-B2 Pyridyl derivatives as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2021-03-02 US disclosed
EP-3440069-B1 PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2020-10-28 EP disclosed
US-20190119248-A1 PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2019-04-25 US disclosed
US-20190119248-A1 PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2019-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10934272-B2 Pyridyl derivatives as bromodomain inhibitors BRD4, BRD3, BRDT BRD4 1/4885NPC1 1233/4885RAB9A 3459/4885
US-20190119248-A1 PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS BRD4, BRD3, BRDT BRD4 1/4885NPC1 1233/4885RAB9A 3459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.